门冬胰岛素联合吡格列酮二甲双胍治疗糖尿病患者的临床效果及安全性

目的探究门冬胰岛素联合吡格列酮二甲双胍治疗糖尿病患者的临床效果及安全性。方法 90例糖尿病患者,采取随机数字表法分为观察组与对照组,各45例。对照组给予门冬胰岛素30治疗,观察组在对照组基础上加用吡格列酮二甲双胍治疗。对比两组治疗前后的血糖相关指标、胰岛素用量、不良反应发生率。结果治疗后,观察组空腹血糖(5.66±1.09)mmol/L、餐后2 h血糖(9.80±1.97)mmol/L、糖化血红蛋白(6.40±1.15)%均低于对照组的(8.57±1.25)mmol/L、(15.43±3.09)mmol/L、(7.85±1.27)%,差异有统计学意义(P<0.05)。观察组治疗期间胰岛素用量(32.78±5.50)U少于对照组的(41.08±6.33)U,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论门冬胰岛素联合吡格列酮二甲双胍治疗糖尿病患者可取得较好的降低血糖水平的目的,安全性高。

Clinical effect and safety of insulin aspart combined with pioglitazone and metformin in the treatment of diabetes mellitus patients

Objective To investigate the clinical effect and safety of insulin aspart combined with pioglitazone and metformin in the treatment of diabetes mellitus patients.Methods A total of 90 cases of diabetes mellitus patients were divided into observation group and control group by random numerical table,with 45 cases in each group.The control group was treated with insulin aspart 30,and the observation group was treated with pioglitazone and metformin on the basis of the control group.The blood glucose-related indicators and insulin dosage before and after treatment,and incidence of adverse reactions were compared between the two groups.Results After treatment,the fasting blood glucose(5.66±1.09) mmol/L,2 h postprandial blood glucose(9.80±1.97) mmol/L,and glycosylated hemoglobin(6.40±1.15)% of the observation group were lower than(8.57±1.25) mmol/L,(15.43±3.09) mmol/L,and(7.85±1.27)% of the control group,and the difference was statistically significant(P<0.05).The insulin dosage(32.78±5.50) U of the observation group during treatment was less than(41.08±6.33) U of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Insulin aspart combined with pioglitazone and metformin in the treatment of diabetes mellitus patients can achieve a better reduction of blood glucose level with high safety.